However, the recent SURMOUNT OSA trial showed the key role of weight loss with tirzepatide, a dual glucagon like peptide 1—(GLP-1) glucose-dependent insulinotropic polypeptide (GIP) analogs showed clinically significant reductions in body weight, the severity of OSA (as measured by apnea hypopnea index), blood pressure, and inflammation with GLP-1A therapy [112,113]. The gene discussed is GIP; the disease is obstructive sleep apnea syndrome.